Background: Cryoprecipitate (CRYO) is a plasma component containing high concentrations of factor VIII (FVIII), von Willebrand factor (VWF), and fibrinogen. Because Greyhounds are reported to have lower plasma VWF and fibrinogen concentrations, their plasma may not yield high potency CRYO.
activity (FVIII:C) in dogs with hemophilia A. 2 The main advantage of CRYO over FFP is a higher concentration of hemostatic proteins in a smaller volume, with a CRYO transfusion thereby resulting in therapeutic concentrations of deficient factors without the risk of volume overloading the recipient. 3 With the availability of recombinant human FVIII and VWF proteins, CRYO now primarily is used in humans for management of acquired hypofibrinogenemia and dysfibrinogenemia. 4, 5 However, studies in the 1960s and 1970s focused on FVIII because CRYO was used for management of hemophilia A at that time. A study evaluating variables that influenced the potency of human CRYO, defined by factor content (IU/unit or mg/unit), concluded that donor plasma FVIII activity was significantly associated with the potency of CRYO, but the plasma FVIII activity varied as much as 6-fold on repeat visits of the same donor. 6 Furthermore, high donor plasma FVIII activity did not always correspond to good recovery of FVIII in CRYO, suggesting that "cryoprecipitability" of FVIII varies from donor to donor. 7 Because of wide interindividual variations in plasma FVIII and VWF concentrations among healthy dogs, concern exists about uniformity and standard potency of CRYO to treat dogs with hemophilia A or VWD. 8 It has been proposed that the target for transfusion therapy in dogs with VWD or hemophilia A is to increase the recipient's plasma VWF concentration above 35 U/dL or FVIII activity above 30 U/dL, respectively (comparable to 35% or 30%, respectively, of a canine standard assigned a value of 100%). 2 Although Greyhounds are commonly used as blood donors, a previous study has identified lower plasma VWF and fibrinogen concentrations in Greyhounds compared to non-Greyhounds. 8 Greyhound plasma, therefore, may not yield high potency CRYO.
The American Association of Blood Banks (AABB) and the Council of Europe (COE) have established requirements for minimum concentrations of hemostatic proteins in CRYO, but given that CRYO now is administered to humans almost exclusively for fibrinogen disorders, the need to regulate the FVIII concentration has been questioned. 9 Nevertheless, AABB and COE standards require that CRYO contain ≥80 and ≥70 IU/unit of FVIII, respectively. Only the COE has set a minimum requirement for VWF of 100 IU/unit. The AABB and COE minimum standards for fibrinogen are 150 mg/unit and 140 mg/unit, respectively. Similar standards have not been established for CRYO production in dogs.
Our objectives were to determine if: (1) canine donor plasma hemostatic protein concentration is a good predictor of CRYO potency; (2) there is a difference in quality of CRYO prepared from
Greyhounds versus non-Greyhounds; and (3) canine CRYO produced by our institution's protocol meets blood banking standards used for humans.
| MATERIALS AND METHODS

| Canine blood donors
Blood used in the study was obtained from 40 dogs, 20 Greyhounds and 20 non-Greyhounds, enrolled in our institution's volunteer blood donor program as part of a standard blood donation (ie, blood components were prepared for patient use, with small aliquots obtained for the study). Canine donor requirements include body weight ≥25 kg, age 1-8 years, and good health, based on history, physical examination, and annual screening that includes a CBC, biochemistry profile, and testing for blood-borne pathogens, as outlined in the updated consensus statement of American College of Veterinary Internal Medicine. 10 In addition, dogs had not been transfused previously and were not receiving any medications, other than heartworm preventative and flea and tick control. Dogs donated blood approximately 4 times per year (average of every 3 months).
| Blood collection and processing
Blood (450 AE 15 mL) was collected from the jugular vein using a stan- All whole blood units and plasma components (FFP, CPP, and CRYO) were weighed using a gram scale to determine the volumes of each. Calculations were based on whole blood having a density of 
| Reproducibility of CRYO potency
To determine if CRYO quality was consistent for an individual canine blood donor, 3 dogs that produced CRYO with acceptable FVIII content (according to AABB standards) and 3 dogs that produced CRYO with substandard FVIII content were identified, and CRYO was prepared from 2 subsequent blood donations for each of the 6 dogs. Aliquots of plasma components were analyzed for FVIII activity, VWF concentration, and fibrinogen concentration, as described above, with the repeat samples for each donor assayed at the same time to minimize inter-assay variation, although initial samples had been analyzed previously to identify donors for the reproducibility study.
| Statistical analysis
All statistical analyses were performed by standard statistical software association existed between independent variables and the outcome of interest. A P value <.2 was considered significant for data to be included in subsequent inference statistical analysis. For normally distributed dependent variables, a 2-sample t test was performed.
Kruskal-Wallis equality-of-populations rank test was used for outcomes that were non-normally distributed.
3 | RESULTS
| Canine blood donor and baseline component characteristics
Routine Greyhounds compared to non-Greyhounds when the 2 VWF-deficient Doberman Pinschers were excluded from data analysis ( Table 2) .
Three of 40 CRYO units (prepared from 2 VWF-deficient dogs and 1 Greyhound) did not meet the COE standard for VWF (≥100 IU/ unit); the 25th and 50th percentiles for CRYO VWF content were Variables are presented as mean and 95% confidence interval.
180 and 232.5 U/unit, respectively ( Figure 1A ). The mean VWF recovery for all CRYO units was 67.1% (95% CI 61.9-72.3), with no difference between Greyhounds and non-Greyhounds (Table 2) in CRYO VWF content when compared to all 20 non-Greyhounds and a 49.6 U/unit decrease (P = .009) when the 2 VWF-deficient non-Greyhounds were excluded ( Table 3 ). The FPP volume was not associated with CRYO VWF potency. Figure 1B ).
| Factor VIII
Mean FVIII recovery for all CRYO units was 37.1% (95% CI 33.5-40.8), with no significant difference between Greyhounds and non-Greyhounds (Table 2 ). An association existed between FFP FVIII activity and FVIII recovery (P = .01). A positive correlation was found between donor FFP FVIII activity and CRYO FVIII content ( Figure 2B ).
In a linear regression analysis, Greyhound breed and FFP volume did not have any effect on prediction of CRYO FVIII potency beyond FFP FVIII activity (Table 3) . 
| Fibrinogen
Greyhounds had a lower mean plasma fibrinogen concentration (214.3 mg/dL; 95% CI, 194.1-234.5) compared to non-Greyhounds (275.9 mg/dL; 95% CI, 252.5-299.3; P < .001). The fibrinogen content in FFP, CPP, and CRYO was significantly less in units prepared from
Greyhounds compared to non-Greyhounds (Table 2 ). All 20 CRYO units prepared from non-Greyhounds met both the AABB and COE standards for fibrinogen content (≥150 and ≥140 mg/unit, Table 3 ).
| Reproducibility of CRYO potency
Three blood donors with CRYO FVIII meeting the AABB standard (≥80 IU/unit) and 3 blood donors with CRYO FVIII below the standard were identified to evaluate the reproducibility of CRYO potency by determining hemostatic protein content in plasma components prepared from 2 subsequent blood donations (Supporting Information Table S1 ). Greyhounds did not differ from that of other breeds in meeting the minimum human blood banking standards for hemostatic protein content, suggesting that Greyhounds do not need to be excluded from the donor pool for CRYO production. reported in the literature, ranging from 5 to 50 mL. 5 Because the concentration of hemostatic proteins in CRYO varies with the volume of residual plasma, human CRYO potency is defined by factor content (IU/unit or mg/unit), which takes into account factor concentration and CRYO volume.
Similar to the first description of preparation of human CRYO in the mid-1960s, 13,14 the production of CRYO today continues to start with thawing of FFP at 1 C-6 C, followed by centrifugation and removal of the supernatant to leave the cold insoluble precipitate in the bag with a variable amount of plasma. 5 In an effort to maximize CRYO potency, early investigations evaluated steps in CRYO production, as well as influence of donor characteristics, that could impact FVIII recovery; VWF and fibrinogen content were not addressed. 6, 7 The presence of ice crystals in the bag while the supernatant plasma was removed resulted in increased FVIII recovery (51 AE 13%) compared to the absence of ice crystals in the bag (43 AE 18%). 6 In our CRYO production technique, the FFP units were centrifuged when approximately 90% was thawed, resulting in a frozen component still present in the bag as the supernatant was expressed into a satellite bag. Two studies documented marked variability in FVIII content of human CRYO, with the only donor characteristic consistently related to CRYO potency being plasma FVIII concentration. 6, 7 One study 7 found an association between donor plasma FVIII concentration and "cryoprecipitability" or recovery of FVIII, whereas the other study 6 found no relationship between these 2 variables. In a study of 169 donors, recovery of plasma FVIII in CRYO ranged from 11.2% to 89.4% (mean 38 AE 18%), and FVIII content of CRYO ranged from 29 to 379 IU/unit (mean, 111 AE 77 IU/unit). 6 In addition, plasma FVIII concentration varied as much as 6-fold on repeated visits of the same donor, suggesting that it is not possible to predict that an individual donor will consistently produce high potency CRYO with regard to FVIII content. 6 Similar to these early investigations with human CRYO, results of our study indicate that a positive correlation exists between canine donor plasma FVIII activity and CRYO FVIII content, as well as donor plasma VWF and fibrinogen concentration and their respective CRYO content. Variability in canine donor coagulation factor activity and VWF concentration has been documented previously. 15 In addition, of 9 coagulation factors and hemostatic proteins measured in plasma samples from 38 donor dogs, plasma FVIII has been noted to have the greatest variability among canine donors, ranging from 31% to 225%. 8 Fresh plasma obtained from 4 monthly blood collections from 7 healthy Greyhounds had inter-assay coefficients of variation ranging from 11% to 34.9% for VWF and from 7.1% to 39% for FVIII. 15 Variations in plasma FVIII, VWF, and fibrinogen content were noted for each of the 6 dogs in our study donating blood on 3 occasions (total of 18 units), yet the variability had little to no effect on CRYO units meeting the minimum blood banking standards for fibrinogen (all 18 units met the AABB criteria of ≥150 mg/unit) and VWF (17 of 18 units met the COE criteria of ≥100 IU/unit) used in humans. However, the factor content of CRYO units not only depends on initial FFP factor concentration but also on factor recovery, which can vary with processing technique, as well as donor-specific attributes of the plasma. 7 Of the 3 proteins evaluated in our study, the mean recovery was highest for VWF (67%), followed by fibrinogen (47%) and FVIII Relatively little information on canine CRYO is available in the veterinary literature. An early report on the administration of CRYO to 2 German Shepherd puppies with hemophilia A indicated that the mean half-life of FVIII in CRYO, based on time for the partial thromboplastin time to return to pre-CRYO results after 6 separate administrations, was 13.2 hours, ranging from 7.7 to 32.3 hours. 16 The mean CRYO FVIII recovery was 26.6%, ranging from 9.2% to 66%, exhibiting wide variability as noted in our study. In a subsequent study evaluating stability of VWF and FVIII in canine CRYO under various storage conditions, CRYO was prepared from 7 Greyhounds given desmopressin 30-60 minutes before blood collection in an effort to increase donor plasma VWF and FVIII concentrations. 17 The CRYO production method involved thawing FFP units in a 4 C water bath (rather than in a refrigerator as used in our study) and leaving 60 mL of plasma in the CRYO unit. Although results were not reported as hemostatic protein content per unit, based on our calculations (assuming a 60 mL CRYO volume), the mean FVIII and VWF contents were 87 and 169 U/unit, respectively. 17 Results of this study indicated that thawed canine CRYO can be maintained for 24 hours at room temperature without substantial reduction in FVIII or VWF. 17 In another study by the same investigators, whole blood again was obtained from Greyhounds pre-treated with desmopressin, and FFP was thawed in a 4 C water bath to produce CRYO. 2 The mean CRYO volume was 37 mL, and we calculated the mean FVIII and VWF contents to be 54 and 151 U/unit, respectively, with reported mean FVIII and VWF recoveries being 23% and 59%, respectively. 3 In a recent study comparing colloid osmotic pressure and concentrations of albumin, VWF and coagulation proteins in canine CPP, CRYO, and FFP, the authors confirmed that their CRYO production method (similar to ours) yielded CRYO units having higher concentrations of FVIII, VWF, and fibrinogen compared to FFP and CPP. 18 However, we cannot directly compare results of this study to ours because the CRYO volume was not specified; CRYO was reportedly split into satellite bags containing 9-30 mL, so the total volume is unclear. Reporting canine CRYO hemostatic protein content as U/unit (for FVIII and VWF) or mg/unit (fibrinogen), as done in publications describing CRYO content in humans, would improve our ability to interpret and compare results of different studies.
Our study was not designed to set blood banking guidelines for minimum factor content for canine CRYO. However, in comparing our 25th percentiles for CRYO hemostatic protein content to blood banking standards used in humans, the COE minimum of ≥100 IU/unit for VWF appears low for canine CRYO, with 75% of our units having ≥180 U/ unit. On the other hand, relatively poor FVIII recovery in canine CRYO resulted in 25% of our units having FVIII content ≤67 U/unit, less than both the AABB (≥80 IU/unit) and COE (≥70 IU/unit) minimum standards. Because we evaluated only a single method of CRYO production, it is unclear whether alterations to the process could improve yield of FVIII in CRYO units or whether a species difference will persist regardless of technique. Finally, 75% of our canine CRYO units had a fibrinogen content >209 mg/unit, similar to the AABB and COE minimum standards of 150 and 140 mg/unit, respectively.
The limitations of our study include comparison of the potency of our CRYO units to blood banking standards used in humans because similar standards have not yet been established for dogs. In addition,
we evaluated only 1 method of CRYO production, which is used by our institution's blood bank, as 1 of our goals was to determine if our method produces CRYO of acceptable quality. Furthermore, reproducibility of CRYO potency was evaluated in only 6 dogs with 3 donations each because of limited funding for the study. Finally, we did not evaluate the efficacy of the CRYO units in increasing hemostatic protein concentration and preventing or controlling bleeding in recipients with VWD, hemophilia A, or fibrinogen disorders, because doing so was beyond the scope of our study.
In conclusion, the factor concentration in donor FFP is associ- 
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